Cervomed Inc Quick Ratio (CRVO) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Cervomed Inc   (NASDAQ: CRVO)

Cervomed Inc 's Quick Ratio

CRVO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2026, Quick Ratio fell to 5.69 below Cervomed Inc average.

Within Major Pharmaceutical Preparations industry 165 other companies have achieved higher Quick Ratio than Cervomed Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 140 to 549.

Explain Quick Ratio?
How much Cash & cash equivalents CRVO´s has?
What are CRVO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CRVO Quick Ratio (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1
Y / Y Current Liabilities Change -42.37 % -37.18 % -58.44 % -42.57 % 48.17 %
Y / Y Cash & cash equivalent Change -63.33 % -46.39 % -41.5 % -25.64 % 453.36 %
Quick Ratio MRQ 5.69 14.35 20.23 18.17 8.94
CRVO's Total Ranking # 549 # 140 # 120 # 72 # 277
Seq. Current Liabilities Change 56.28 % 7.77 % -26.9 % -53.19 % 70.35 %
Seq. Cash & cash equivalent Change -38.06 % -23.56 % -18.6 % -4.86 % -9.45 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 166
Healthcare Sector # 256
Overall Market # 549


Quick Ratio Statistics
High Average Low
20.23 6.49 0.01
(Sep 30 2025)   (Mar 31 2013)




Financial Statements
Cervomed Inc 's Current Liabilities $ 2 Millions Visit CRVO's Balance sheet
Cervomed Inc 's Cash & cash equivalent $ 13 Millions Visit CRVO's Balance sheet
Source of CRVO's Sales Visit CRVO's Sales by Geography


Cumulative Cervomed Inc 's Quick Ratio

CRVO's Quick Ratio for the trailling 12 Months

CRVO Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth -45.58 % -24.87 % -6.34 % 21.91 % 56.41 %
Y / Y Cash & cash equivalent TTM Growth -42.97 % -14.67 % 27.46 % 121.52 % 526.33 %
Quick Ratio TTM 13.67 13.61 14.28 13.6 13.05
Total Ranking TTM # 3391 # 0 # 0 # 0 # 0
Seq. Current Liabilities TTM Growth -19.44 % -9.1 % -16.72 % -10.76 % 11.21 %
Seq. Cash & cash equivalent TTM Growth -19.09 % -13.38 % -12.54 % -6.97 % 21.07 %

Quick ratio ranking by company, industry and sector >> Back to CRVO Financial Strength Comparisons >> Go to Compare CRVO Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Cervomed Inc 's average Cash & cash equivalent, this led to increase in in Cervomed Inc 's Quick Ratio to 13.67, above CRVO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 414 other companies have achieved higher Quick Ratio than Cervomed Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 0 to 3391.

Explain Quick Ratio?
How much Cash & cash equivalents CRVO´s has?
What are CRVO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 415
Healthcare Sector # 844
Within the Market # 3391


trailing twelve months Quick Ratio Statistics
High Average Low
9.91 9.63 9.35
(Dec 31 2025)   (Mar 31 2026)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Rezolute Inc   15.61 $ 120.268  Millions$ 7.704  Millions
Bioage Labs Inc   15.38 $ 243.457  Millions$ 15.827  Millions
An2 Therapeutics Inc   15.33 $ 85.288  Millions$ 5.562  Millions
Roivant Sciences Ltd   15.26 $ 4,291.833  Millions$ 281.244  Millions
Gri Bio Inc   15.01 $ 11.048  Millions$ 0.736  Millions
Ocular Therapeutix Inc   14.98 $ 666.699  Millions$ 44.513  Millions
Cogent Biosciences Inc   14.94 $ 866.378  Millions$ 57.981  Millions
Pepgen Inc   14.76 $ 132.303  Millions$ 8.964  Millions
Spruce Biosciences Inc   14.68 $ 54.080  Millions$ 3.683  Millions
Coya Therapeutics Inc   14.30 $ 50.725  Millions$ 3.547  Millions
Sensei Biotherapeutics Inc   14.29 $ 202.793  Millions$ 14.190  Millions
Vtv Therapeutics Inc   14.25 $ 98.086  Millions$ 6.881  Millions
Jade Biosciences Inc   13.96 $ 311.295  Millions$ 22.292  Millions
Bicara Therapeutics Inc   13.72 $ 539.753  Millions$ 39.340  Millions
Onkure Therapeutics Inc   13.41 $ 192.106  Millions$ 14.329  Millions
Crescent Biopharma Inc   13.33 $ 189.163  Millions$ 14.193  Millions
Vera Therapeutics Inc   13.22 $ 596.760  Millions$ 45.149  Millions
Arrivent Biopharma inc   13.06 $ 326.380  Millions$ 24.995  Millions
Savara Inc   13.05 $ 202.772  Millions$ 15.539  Millions
Unicycive Therapeutics Inc  13.02 $ 54.586  Millions$ 4.192  Millions
Neurogene Inc   12.89 $ 243.182  Millions$ 18.866  Millions
Seaport Therapeutics Inc   12.84 $ 182.605  Millions$ 14.223  Millions
Nkarta Inc   12.66 $ 230.428  Millions$ 18.207  Millions
Theravance Biopharma inc   12.42 $ 394.666  Millions$ 31.775  Millions
Atrium Therapeutics Inc   12.23 $ 267.849  Millions$ 21.905  Millions
Zenas Biopharma Inc   11.73 $ 717.205  Millions$ 61.161  Millions
Bicycle Therapeutics Plc  11.44 $ 559.474  Millions$ 48.889  Millions
Rallybio Corporation  11.30 $ 46.795  Millions$ 4.140  Millions
Pmv Pharmaceuticals Inc   11.27 $ 93.549  Millions$ 8.302  Millions
Whitehawk Therapeutics Inc   11.13 $ 123.043  Millions$ 11.056  Millions

Date modified: 2026-08-29T17:26:37+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.